ABRAHAM KIMELI: Open Payments
NPI 1215404413 · SAGINAW, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,733 in 237 payments from 18 companies in 2025. Trend: 2023 $3,346 · 2024 $2,654 · 2025 $3,733
Food & beverage: $3,733
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 41 | $617 |
| Alkermes, Inc. | 19 | $406 |
| Vanda Pharmaceuticals Inc. | 27 | $367 |
| Neurocrine BioSciences, Inc. | 22 | $341 |
| Lundbeck LLC | 12 | $256 |
| Janssen Pharmaceuticals, Inc | 13 | $248 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $214 |
| Collegium Pharmaceutical, Inc. | 17 | $205 |
| Axsome Therapeutics, Inc. | 9 | $194 |
| E.R. Squibb & Sons, L.L.C. | 21 | $192 |
Products named: REXULTI, ARISTADA, INGREZZA, FANAPT, ABILIFY ASIMTUFII, CAPLYTA, Jornay PM, Auvelity.
Industry payments across MI — which companies pay providers there.
